Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Finished Goods Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Dna X (SONM) Current Leases (2022 - 2023)

Dna X filings provide 2 years of Current Leases readings, the most recent being $55000.0 for Q4 2023.

On a quarterly basis, Current Leases fell 16.67% to $55000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $55000.0, a 16.67% decrease, with the full-year FY2023 number at $55000.0, down 16.67% from a year prior.
Current Leases hit $55000.0 in Q4 2023 for Dna X, down from $120000.0 in the prior quarter.
In the past five years, Current Leases ranged from a high of $769000.0 in Q1 2022 to a low of $55000.0 in Q4 2023.